Aurinia Pharmaceuticals AUPH

$ 8.49 3.09%

Quarterly report 2024-Q3
added 11-07-2024

Aurinia Pharmaceuticals Balance Sheet 2011-2024 | AUPH

Annual Balance Sheet Aurinia Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	27.7 M	-86 M	-223 M	-	-306 M	-118 M	-166 M	-39.6 M	-5.76 M	-22.7 M	-1.82 M	-149 K	-5.84 M
Long Term Debt	75.5 M	7.15 M	7.68 M	-	-	-	-	-	-	-	-	-	35.3 K
Long Term Debt Current	989 K	936 K	1.06 M	788 K	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	41.9 M	26 M	16 M	13.1 M	9.99 M	4.44 M	3.8 M	2.61 M	5.78 M
Total Current Liabilities	77.2 M	46.1 M	40.6 M	32 M	-	-	-	-	-	-	-	-	-
Total Liabilities	170 M	65.4 M	64.3 M	55.9 M	53.2 M	33.3 M	24.1 M	21 M	13.6 M	7.27 M	9.84 M	6.28 M	7.91 M
Deferred Revenue	4.81 M	3.15 M	190 K	-	118 K	118 K	118 K	118 K	168 K	217 K	227 K	340 K	1.22 M
Retained Earnings	-942 M	-864 M	-756 M	-575 M	-540 M	-416 M	-352 M	-281 M	-258 M	-236 M	-205 M	-217 M	-202 M
Total Assets	548 M	471 M	543 M	464 M	327 M	146 M	190 M	57 M	33.6 M	52.4 M	23.1 M	4.16 M	14.3 M
Cash and Cash Equivalents	48.8 M	94.1 M	232 M	272 M	306 M	118 M	-	-	-	-	-	-	-
Book Value	378 M	405 M	479 M	408 M	274 M	113 M	166 M	36 M	20 M	45.1 M	13.3 M	-2.12 M	6.41 M
Total Shareholders Equity	378 M	405 M	479 M	408 M	299 M	136 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Aurinia Pharmaceuticals

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	66 M	64.9 M	67.5 M	75.5 M	72.2 M	79.4 M	6.99 M	7.15 M	7.27 M	-	7.56 M	7.68 M	7.8 M	7.82 M	7.81 M	7.62 M	7.62 M	7.62 M	7.62 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	161 M	159 M	157 M	170 M	163 M	157 M	61.4 M	65.4 M	64.9 M	-	58.8 M	64.3 M	61.9 M	54 M	46.8 M	55.9 M	55.9 M	55.9 M	55.9 M	25.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	4.3 M	4.37 M	4.91 M	4.81 M	4.66 M	3.23 M	3.16 M	3.15 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-938 M	-952 M	-953 M	-942 M	-915 M	-902 M	-891 M	-864 M	-838 M	-	-794 M	-756 M	-723 M	-673 M	-626 M	-575 M	-575 M	-575 M	-575 M	-472 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	549 M	524 M	517 M	548 M	555 M	549 M	452 M	471 M	488 M	-	507 M	543 M	360 M	386 M	417 M	464 M	464 M	464 M	464 M	324 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	36.6 M	33.3 M	63.9 M	48.9 M	45.6 M	81.4 M	88.3 M	94.2 M	85.3 M	151 M	132 M	232 M	57.6 M	122 M	157 M	272 M	272 M	272 M	272 M	306 M	-	-	-	118 M	-	-	-	166 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	388 M	365 M	359 M	378 M	392 M	392 M	390 M	405 M	423 M	-	448 M	479 M	298 M	332 M	370 M	408 M	408 M	408 M	408 M	299 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	388 M	365 M	359 M	378 M	392 M	392 M	390 M	405 M	423 M	424 M	448 M	479 M	298 M	332 M	370 M	408 M	408 M	408 M	408 M	299 M	-	-	-	136 M	-	-	-	178 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency